The price of Insulet Corporation (NASDAQ:PODD) shares last traded on Wall Street fell -1.56% to $307.89.
Based on available information, 19 analysts follow Insulet Corporation (NASDAQ:PODD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $375.00 and a low of $292.00, we find $340.00. Given the previous closing price of $312.77, this indicates a potential upside of 8.71 percent. PODD stock price is now 5.54% away from the 50-day moving average and 16.48% away from the 200-day moving average. The market capitalization of the company currently stands at $21.62B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 5 rate the stock a hold while 10 rate it a buy. Brokers who have rated the stock have averaged $338.40 as their price target over the next twelve months.
On November 04, 2022, Piper Sandler Upgraded its previous ‘Neutral’ rating to ‘Overweight’ on the stock increasing its target price from $235 to quote $340, while ‘Barclays’ rates the stock as ‘Equal Weight’.
In other news, Alpuche Charles, Advisor sold 23,401 shares of the company’s stock on Mar 13. The stock was sold for $7,140,815 at an average price of $305.15. Upon completion of the transaction, the Advisor now directly owns 45,584 shares in the company, valued at $14.03 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 09, Advisor Alpuche Charles sold 4,000 shares of the business’s stock. A total of $1,163,600 was realized by selling the stock at an average price of $290.90. This leaves the insider owning 45,584 shares of the company worth $14.03 million. Insiders disposed of 161,372 shares of company stock worth roughly $49.68 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PODD stock. A new stake in Insulet Corporation shares was purchased by SCOUT INVESTMENTS, INC. during the first quarter worth $47,404,000. ALYESKA INVESTMENT GROUP, L.P. invested $41,490,000 in shares of PODD during the first quarter. In the first quarter, PORTMAN SQUARE CAPITAL LLP acquired a new stake in Insulet Corporation valued at approximately $23,062,000. SQUAREPOINT OPS LLC acquired a new stake in PODD for approximately $14,417,000. BROOKFIELD CORP /ON/ purchased a new stake in PODD valued at around $13,463,000 in the second quarter.
A candlestick chart of Insulet Corporation (NASDAQ: PODD) showed a price of $309.60 on Wednesday morning. During the past 12 months, Insulet Corporation has had a low of $181.00 and a high of $320.00. As of last week, the company has a debt-to-equity ratio of 2.94, a current ratio of 3.60, and a quick ratio of 2.70. The fifty day moving average price for PODD is $292.00 and a two-hundred day moving average price translates $264.72 for the stock.
The latest earnings results from Insulet Corporation (NASDAQ: PODD) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.08, missing analysts’ expectations of $0.15 by -0.23. This compares to $0.44 EPS in the same period last year. The net profit margin was 0.40% and return on equity was 1.00% for PODD. The company reported revenue of $369.7 million for the quarter, compared to $307.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 20.15 percent. For the current quarter, analysts expect PODD to generate $330.43M in revenue.
Insulet Corporation(PODD) Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
